Skip to main content
. Author manuscript; available in PMC: 2018 Jan 9.
Published in final edited form as: Toxicol Appl Pharmacol. 2016 Sep 20;311:106–112. doi: 10.1016/j.taap.2016.09.016

Fig. 5.

Fig. 5

Apigenin inhibits NEDD9-Src-Akt signaling cascade. (A) DLD1 cells were treated with various doses of apigenin (APG) for 24 h. mRNA level of NEDD9 was measured by RT-PCR. (B) DLD1 cells were pretreated with MG132 for 4 h prior to APG treatment. After 24 h, the cells were collected for examination of NEDD9 expression by immunoblotting analysis. (C) DLD1 and SW480 cells were treated with APG at indicated doses for 24 h. Whole cell lysate were isolated and protein expression was analyzed by immunoblotting analysis. (D) DLD1 cells and SW480 cells with or without knockdown of NEDD9 were treated with 40 μM of APG for 24 h. Whole cell lysates were isolated for immunoblotting analysis. (E) DLD1 and SW480 cells with or without stable overexpression of NEDD9 were treated with 40 μM of APG for 24 h. Whole cell lysates were isolated for immunoblotting analysis. The results from immunoblotting analyses are representative of three independent experiments.